Results 181 to 190 of about 315,782 (393)

Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department [PDF]

open access: bronze, 2015
Michael D. Brown   +29 more
openalex   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem   +5 more
wiley   +1 more source

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology [PDF]

open access: gold, 2018
Jordan Gainey   +6 more
openalex   +1 more source

Diagnostic and Prognostic Values Of Serum C-Reactive Protein, Procalsitonin, Soluable Urokinase Plasminogen Activator Receptor (suPAR) and Neopterin Levels in Hospitalized Patients in Intensive Care Unit with Ventilator Associated Pneumonia

open access: diamond, 2021
Reyhan Öztürk   +9 more
openalex   +1 more source

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

open access: yesBritish Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro   +12 more
wiley   +1 more source

Tissue-Type Plasminogen Activator Deficiency Exacerbates Arthritis [PDF]

open access: bronze, 2001
Yuan Yang   +2 more
openalex   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy